But when activated in parallel with GLP-1 and GIP, it increases resting energy expenditure, mobilizes hepatic fatty acids, and amplifies fat loss without compromising glycemic control, thanks to its simultaneous incretin component
But in combination with significantly reduced food intake, blood sugar can fluctuate in ways that contribute to fatigue
Tirzepatide (Mounjaro/Zepbound) Timeline Phase 3 trials began: 2019 (SURPASS program for diabetes) FDA approval (Mounjaro for diabetes): May 2022 Commercial availability: June 2022, initial supply constraints Zepbound (obesity indication) Phase 3: 2020-2022 (SURMOUNT program) Zepbound FDA approval: November 2023 Zepbound commercial launch: December 2023, immediate shortages Stable widespread availability: Still not fully stable as of early 2026
The exact dose, frequency, and cycle length we use at Perfect B is broken down in our dedicated MOTS-c dosage and injection protocol guide covering reconstitution, timing, and cycle structure